Breaking News, Collaborations & Alliances

Patheon to Manufacture FDA-Approved Nasal Spray

Evoke Pharma initiates commercial manufacturing of Gimoti with the CDMO.

By: Contract Pharma

Contract Pharma Staff

Evoke Pharma, a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, has initiated the commercial manufacturing of Gimoti (metoclopramide) nasal spray with its manufacturing partner, Patheon, a division of Thermo Fisher Scientific. Gimoti was approved by the U.S. FDA on June 19, 2020 for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. The company plans to launch sales of Gimoti in the fourth quarter 2020 with its partner Eve...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters